NCT06474442招募中2 期
A Multicenter, Single-blind, Single-dose, Randomized, Phase Ⅱa Trial to Evaluate the Safety, Tolerability and Efficacy of Intrastromal BD111 Gene Editing Therapy in Adults With HSV-1 Stromal Keratitis
Shanghai BDgene Co., Ltd.1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2025年4月28日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Clinical cure rate of HSK at Day 70 and Day112 post-administration
研究概览
简要总结
This study aims to compare the clinical efficacy and safety of BD111 injection in combination with standard therapy vs. standard therapy in herpes simplex virus type I stromal keratitis (HSK), providing preliminary confirmation of the clinical effectiveness of BD111 in combination with standard therapy.
详细描述
This is a phase Ⅱa, single-blind, single-dose, randomized, positively controlled clinical trial of BD111 in patients with herpes simplex virus type I stromal keratitis (HSK) aged 18 to 70 years. Forty eligible participants will be recruited in the trial. BD111 is investigational new biologics (Injection)--a type of lentiviral-like particle that can simultaneously deliver SpCas9 and gRNA targeting the HSV-1 virus gene, also known as HSV-1-erasing lentiviral particles (HELP). The total follow-up duration was 12 months, the safe endpoints and efficacy endpoints will be used to assess the efficacy, safety and tolerability profiles in patients with HSK.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must meet all of the following inclusion criteria to be enrolled in this study.
- •Aged 18 to 70 years old;
- •Clinically diagnosed with herpes simplex virus stromal keratitis;
- •Tear swab HSV-1 nucleic acid test (qPCR method) positive;
- •No use of systemic antiviral drugs or corticosteroids within 48 hours before enrollment;
- •No systemic immune eye diseases;
- •Good eyelid structure and blinking function;
- •Eye structure and function assessment showing potential for visual recovery;
- •No retinal detachment, with generally normal visual function;
- •No history of corneal trauma;
- •Visual acuity in the fellow eye is better than 20/200;
- •Fertile males or females must use highly effective contraceptive methods (such as oral contraceptives, intrauterine devices, abstinence, or barrier contraception combined with spermicides) during the trial and continue contraception for 12 months after administration;
- •Participants voluntarily join the study, sign an informed consent form, have good compliance, and cooperate with follow-up visits.
排除标准
- •Patients with any of the following conditions cannot be enrolled in this study
- •Active ocular infection caused by other pathogens in the target eye or the fellow eye within 30 days before enrollment, including but not limited to blepharitis, infectious conjunctivitis, keratitis, scleritis, and endophthalmitis;
- •Patients with bilateral viral keratitis
- •Previous corneal transplant surgery in the study eye;
- •A history of adverse reactions or allergies to corticosteroids and sodium fluorescein, allergies to therapeutic or diagnostic protein products, allergies to ≥ two drugs or non-drug factors, or having an ongoing allergic disease;
- •Absence of tear film and blinking function;
- •Severe dry eye disease;
- •Malignant ocular surface tumor;
- •Patients with systemic autoimmune diseases;
- •Signs of systemic infection before enrollment, including fever and receiving antibiotic treatment (abnormal elevating values in white blood cells, lymphocytes, and neutrophils in routine blood tests);
- •Abnormal major organ function or other uncontrolled clinical problems, mainly including but not limited to the following:
- •Severe kidney disease history, serum creatinine ≥ 133μmol/L;
- •Liver dysfunction, transaminase level ≥ 80 IU/L;
- •Uncontrolled hypertension, systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg;
- •Uncontrolled diabetes, fasting blood glucose greater than or equal to 8.0 μmol/L;
- •Cardiovascular disease history, with arrhythmia, myocardial ischemia, and myocardial infarction (diagnosed by electrocardiogram examination);
- •Platelet level ≤ 100×10^9/μL or ≥ 450×10^9/μL due to any cause, hemoglobin level lower than 10.0g/dL (male) or 9.0g/dL (female).
- •HIV infection;
- •Pregnant and lactating women (pregnancy in this trial is defined as a positive urine pregnancy test);
- •Participation in other drug or medical device clinical trials;
- •Alcohol or drug abuse;
- •Lack of compliance with the trial or the ability to sign an informed consent form;
- •Other situations deemed unsuitable for participation in the trial by the investigator.
结局指标
主要结局
Clinical cure rate of HSK at Day 70 and Day112 post-administration
时间窗: 12 months
Definition of HSK clinical cure: disappearance of the subject's clinical symptoms, disappearance of active inflammatory lesions on ophthalmologic examinations, and successful clearance of the HSV-1 viral genome.
次要结局
- The percentage of participants with successful clearance of HSV-1 viral genome in tears at Day 14, Day 28, Day 70, Day 112, Day 180, and Day 365 post-administration(12 months)
- The percentage of participants with HSK recurrence at Day 180, and Day 365 post-administration(12 months)
- Score change of corneal inflammation scale post-administration(12 months)
- Anti-p24 antibody in blood(12 months)
- Vector RNA copy number in tear fluid(12 months)
- The percentage of participants with failed clearance of HSV-1 viral genome in tears at Day 14, Day 28, Day 70, Day 112, Day 180, and Day 365 post-administration(12 months)
- Anti-Cas9 antibody in blood(12 months)
- Circular DNA copy number in blood(12 months)
- The improvement in corrected distance visual acuity (CDVA) post-administration(12 months)
- Anti-BD111 antibody in blood(12 months)
- Off-target Detection(6 months)
- The improvement in best corrected visual acuity (BCVA)(12 months)
- The characteristics of adverse events (AEs) and serious adverse events (SAEs)(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated VasculitisANCA-associated VasculitisNCT05197842Staidson (Beijing) Biopharmaceuticals Co., Ltd93
已完成
1 期
Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)Hidradenitis SuppurativaNCT05103423Staidson (Beijing) Biopharmaceuticals Co., Ltd50
已完成
3 期
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT00805194Boehringer Ingelheim1,314
已完成
2 期
Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)Hidradenitis SuppurativaNCT05093855Staidson (Beijing) Biopharmaceuticals Co., Ltd41
终止
1 期
Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy ParticipantsAchondroplasiaNCT05813314BioMarin Pharmaceutical36